Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Cassava Sciences (NASDAQ: SAVA), a biotechnology company specializing in novel treatments for central nervous system (CNS) disorders, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, Rick Barry, will deliver a corporate presentation on Monday, September 8, 2025, at 5 PM ET in New York City. The presentation will be available via webcast, with a replay accessible on Cassava's investor website for approximately 90 days after the event.
Cassava Sciences (NASDAQ: SAVA), una società biotecnologica specializzata in nuovi trattamenti per i disturbi del sistema nervoso centrale (SNC), ha annunciato la sua partecipazione al prossimo H.C. Wainwright 27th Annual Global Investment Conference.
Il Presidente e CEO dell'azienda, Rick Barry, terrà una presentazione aziendale lunedì 8 settembre 2025 alle 17:00 ET a New York. La presentazione sarà trasmessa in webcast e una registrazione sarà disponibile sul sito per gli investitori di Cassava per circa 90 giorni dopo l'evento.
Cassava Sciences (NASDAQ: SAVA), una compañía biotecnológica especializada en tratamientos novedosos para los trastornos del sistema nervioso central (SNC), ha anunciado su participación en la próxima H.C. Wainwright 27th Annual Global Investment Conference.
El presidente y director ejecutivo de la compañía, Rick Barry, ofrecerá una presentación corporativa el lunes 8 de septiembre de 2025 a las 5:00 PM ET en Nueva York. La presentación se transmitirá por webcast y habrá una reproducción disponible en el sitio web de inversores de Cassava durante aproximadamente 90 días tras el evento.
Cassava Sciences (NASDAQ: SAVA)는 중추신경계(CNS) 질환에 대한 혁신적인 치료법을 개발하는 생명공학 기업으로, H.C. Wainwright 27th Annual Global Investment Conference에 참여한다고 발표했습니다.
회사의 사장 겸 CEO인 Rick Barry가 2025년 9월 8일 월요일 동부시간 오후 5시(ET) 뉴욕에서 기업 발표를 진행합니다. 발표는 웹캐스트로 중계되며, 이벤트 종료 후 약 90일 동안 Cassava의 투자자 웹사이트에서 재시청이 가능합니다.
Cassava Sciences (NASDAQ: SAVA), une société de biotechnologie spécialisée dans de nouveaux traitements des troubles du système nerveux central (SNC), a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference.
Le président-directeur général de la société, Rick Barry, présentera une conférence d'entreprise le lundi 8 septembre 2025 à 17h00 (ET) à New York. La présentation sera diffusée en webcast et une rediffusion sera accessible sur le site investisseurs de Cassava pendant environ 90 jours après l'événement.
Cassava Sciences (NASDAQ: SAVA), ein Biotechnologieunternehmen, das sich auf neuartige Behandlungen von Erkrankungen des zentralen Nervensystems (ZNS) spezialisiert hat, hat seine Teilnahme an der bevorstehenden H.C. Wainwright 27th Annual Global Investment Conference angekündigt.
Der Präsident und CEO des Unternehmens, Rick Barry, wird am Montag, den 8. September 2025, um 17:00 Uhr ET in New York eine Unternehmenspräsentation halten. Die Präsentation wird per Webcast übertragen und eine Aufzeichnung wird für etwa 90 Tage nach der Veranstaltung auf der Investorenseite von Cassava verfügbar sein.
- None.
- None.
AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City.
Rick Barry, President and Chief Executive Officer, will participate in-person at this corporate event.
Conference details are as follows:
H.C. Wainwright 27th Annual Global Investment Conference
Format: Corporate Presentation
Date: Monday, September 8, 2025
Time: 5 PM ET
Webcast Link: Here
A replay of the webcast will be accessible on the Cassava Investor’s website for approximately 90 days following the event.
To request a meeting or for more details about the conference please reach out to your institutional contact.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A protein, which regulates diverse aspects of neuronal development. The Company is based in Austin, Texas.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Investors
Sandya von der Weid
svonderweid@lifesciadvisors.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
IR@cassavasciences.com
FAQ
When is Cassava Sciences (SAVA) presenting at the H.C. Wainwright Conference 2025?
Who will represent Cassava Sciences (SAVA) at the H.C. Wainwright Conference?
How can investors access Cassava Sciences' (SAVA) H.C. Wainwright Conference presentation?
What is Cassava Sciences' (SAVA) main business focus?
